CXCL10 elevation
|
Uveal Melanoma
|
CXCL10 elevation
|
Uveal Melanoma
|
tebentafusp Sensitive: C3 – Early Trials
|
tebentafusp Sensitive: C3 – Early Trials
|
CXCL10 elevation
|
Cutaneous Melanoma
|
CXCL10 elevation
|
Cutaneous Melanoma
|
tebentafusp Sensitive: C3 – Early Trials
|
tebentafusp Sensitive: C3 – Early Trials
|
CXCL10 elevation
|
Endometrial Cancer
|
CXCL10 elevation
|
Endometrial Cancer
|
pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
|
pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
|
CXCL10 elevation
|
AML
|
CXCL10 elevation
|
AML
|
venetoclax Resistant: D – Preclinical
|
venetoclax Resistant: D – Preclinical
|